Disclosed is a composition of matter involving a recombinant
fusion protein comprising a a pharmacologically
active protein partner, and a small pharmacologically inactive
protein domain partner of human origin, such as but not limited to, a 10th
fibronectin III domain, a SH3 domain, a SH2 domain, a CH2 domain of IgG1, a PDZ domain, a
thrombospondin repeat domain, an
ubiquitin domain, a
leucine-rich repeat domain, a villin headpiece HP35 domain, a villin headpiece HP76 domain, or a fragment or modification of any of these. Also disclosed are nucleic acids (e.g.,
DNA constructs) encoding the
fusion protein, expression vectors and recombinant host cells for expression of the
fusion protein, and pharmaceutical compositions containing the recombinant fusion
protein and a pharmaceutically acceptable carrier, and method of producing a pharmacologically active recombinant fusion
protein.